Available kits and services

Adalimumab is a tumor necrosis factor (TNF) inhibitor that can diminish inflammation. It is a fully human monoclonal antibody. 

Read more about adalimumab.
Contact us to order the level or ADA kit. To use our drug level and ADA testing services, fill out this form.

Infliximab is a tumor necrosis factor (TNF) inhibitor that can diminish inflammation. It is a chimeric human/mouse monoclonal antibody.

Read more about Infliximab.
Contact us to order the level or ADA kit. To use our drug level and ADA testing services, fill out this form.

Etanercept competitively inhibits TNF binding to its cell surface receptors, thereby inhibiting the biological activity of TNF.

Read more about etanercept.
Request form service testing

Certolizumab binds with high affinity to human TNFα, thereby neutralizing this pro-inflammatory cytokine, which can relieve signs and symptoms in patients with inflammatory conditions. 

Read more about certolizumab.
To use our drug level and ADA testing services, fill out this form.

Golimumab inhibits the inflammatory response by preventing the interaction of TNF-α with its receptors. 

Read more about golimumab.
To use our drug level and ADA testing services, fill out this form.

Vedolizumab is a monoclonal antibody directed at α4β7 integrin, that reduces inflammation specifically in the gut

Read more about vedolizumab.
To use our drug level and ADA testing services, fill out this form.

Rituximab is a monoclonal antibody directed against CD20 protein present on B‑lymphocytes. Rituximab is used to treat various blood cancers and inflammatory conditions.

Read more about rituximab.
To use our drug level and ADA testing services, fill out this form.

Natalizumab inhibits adhesion-molecule via binding to α4β1 integrin, and is thought to prevent migration of inflammatory cells into the brain in multiple sclerosis. 

Read more about natalizumab.
To use our drug level and ADA testing services, fill out this form.

Abatacept modulates a key costimulatory signal required for full activation of T lymphocytes expressing CD28, thereby dampening T lymphocyte-dependent antibody responses and inflammation.

Read more about abatacept.
To use our drug level testing services, fill out this form.

Ustekinumab is a fully human IgG1κ monoclonal antibody that targets both interleukin-12 and interleukin-23.

Read more about ustekinumab.
To use our drug level and ADA testing services, fill out this form.

Tocilizumab is a humanised IgG1 monoclonal antibody directed against the receptor of the human pro-inflammatory cytokine IL-6.

Read more about tocilizumab.
To use our drug level and ADA testing services, fill out this form.

Eculizumab is a humanised monoclonal antibody that targets human C5 complement protein and inhibits the activation of terminal complement. 

Read more about eculizumab.
To use our level testing services, email us at biologics@sanquin.nl.

Abciximab is a glycoprotein IIb/IIIa receptor antagonist that acts as a platelet aggregation inhibitor. It is used to prevent thrombus formation during coronary artery procedures. Anti-drug-antibodies may form upon treatment with abciximab.

Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), which is overexpressed in about 20-30% of primary breast cancers.

Read more about trastuzumab.
To use our drug level and ADA testing services, fill out this form.

Omalizumab prevents binding of IgE to the high-affinity IgE receptor (FcRI), and thereby reduces the amount of free IgE that is available to trigger the allergic cascade

Read more about omalizumab.
To use our drug level and ADA testing services, fill out this form.

Nivolumab is a human monoclonal antibody directed at PD-1 receptor, a negative regulator of T-cell activity. Nivolumab potentiates T-cell responses, including anti-tumour responses.

Read more about nivolumab.
To use our drug level and ADA testing services, fill out this form.